Home > Insider Trading > Filing (0001209191-16-137319)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1377121	Protagonist Therapeutics Inc	PTGX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619859	L.p. X Canaan	285 Riverside Avenue, Suite 250 Westport CT 06880		Yes	No	Yes	No
1673228	Canaan Partners X Llc	285 Riverside Avenue Suite 250 Westport CT 06880		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-08-16	1,869,922	$0.00	1,869,922	No	4	C	Direct
Common Stock	Acquisiton	2016-08-16	583,333	$12.00	2,453,255	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2016-08-16	27,113,877	$0.00	1,869,922	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

The number of shares of common stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Preferred Stock converted into one share of common stock of the Issuer at the closing of the Issuer's initial public offering.
Each share of the Issuer's Series C Preferred Stock, which had no expiration date, automatically converted into the Issuer's common stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering, for no additional consideration.
These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Julie Papanek, a non-managing member of Canaan X, serves as representative of the Canaan Entities on the Issuer's board of directors. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.